Debiopharm, a privately-owned Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, announces the dosing of the first healthy volunteer in its randomised, double-blind, placebo-controlled, Phase I trial (NCT07035769).
Debiopharm's Debio 1453 aims to enhance the current range of treatment options by offering a novel antibiotic with an entirely new mechanism of action against Neisseria gonorrhoeae (N. gonorrhoeae) infections.
Debiopharm is leveraging its expertise in combating bacterial infections through the development of a new antibiotic with a novel way to target the bacterium.
Ultimately, Debio 1453 has the potential to create a truly novel therapeutic option that's free from current resistance issues and become a durable game changer for patients with gonorrhoea.
“The first clinical administration of our novel antibiotic is a pivotal milestone. This step brings us closer to providing a first-in-class innovative therapeutic option for those affected by gonorrhoea, particularly for patients with hard-to-treat infections where effective treatments are greatly needed," expressed Alireza Shamaei-Tousi, Principal Clinical Scientist.
The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership that accelerates antibacterial research and development to protect lives from bacterial infections, is supporting the development of Debio 1453 with overall funding projected to exceed $20m in total, based on the achievement of predetermined milestones.